## CLAIMS

1. A storage-stable preservative-free ophthalmic atropine composition, comprising:

   an aqueous solution comprising low-dose atropine or a pharmaceutically acceptable salt thereof, a low-strength buffer, a pharmaceutically acceptable salt, and a cellulosic viscosity modifier;

   wherein the low-strength buffer has a concentration of equal or less than 50mM, and wherein the low-dose atropine is present at a concentration of equal or less than 0.05 wt%; and

   wherein the ophthalmic atropine composition contains not more than 0.01 wt% of a preservative.

2. The composition of claim 1, wherein the low-dose atropine is present at a concentration of equal or less than 0.01 wt%.

3. The composition of claim 1, wherein the atropine or a pharmaceutically acceptable salt thereof is present in the ophthalmic atropine composition in an amount of between 0.01% and 0.02 wt%.

4. The composition of claim 1, wherein the atropine or a pharmaceutically acceptable salt thereof is present in the ophthalmic atropine composition in an amount of between 0.001 wt% and 0.01 wt%.

5. The composition of claim 1, wherein the atropine or a pharmaceutically acceptable salt thereof is atropine sulfate.

6. The composition of claim 1, wherein the low-strength buffer comprises a first and a second buffer component.

7. The composition of claim 6, wherein the low-strength buffer comprises monobasic and dibasic sodium phosphate.

8. The composition of claim 1, wherein the ophthalmic atropine composition has a pH of between 5.0 and 6.0.

9. The composition of claim 1, wherein the ophthalmic atropine composition has a pH of between 5.5 (+/- 0.2) and 6.0 (+/- 0.2).

10. The composition of claim 1, further comprising a chelator.

11. The composition of claim 10, wherein the chelator is present in an amount of 0.01wt% (+/- 20% abs.)

12. The composition of claim 10, wherein the chelator is selected from the group consisting of a bicarboxylic acid, a tricarboxylic acid, and an aminopolycarboxylic acid.

13. The composition of claim 1, wherein the pharmaceutically acceptable salt is present in the ophthalmic atropine composition in an amount of between 0.2 wt% and 0.8 wt%.

14. The composition of claim 1, wherein the pharmaceutically acceptable salt is sodium chloride and wherein the salt is present in the ophthalmic atropine composition in an amount of 0.5 wt% ( +/- 0.2 wt%).

15. The composition of claim 1, wherein the cellulosic viscosity modifier is a hydroxyethyl cellulose, a hydroxypropyl cellulose, or a hydroxypropyl methylcellulose.

16. The composition of claim 1, wherein the cellulosic viscosity modifier is present in an amount of 0.5 wt% (+/- 0.1 wt%) of the ophthalmic atropine composition.

17. The composition of claim 1, wherein the ophthalmic atropine composition is formulated such that after storage over at least two months at 25 ºC and 60% relative humidity equal or less than 0.35% tropic acid is formed from degradation of the atropine.

18. The composition of claim 1, wherein the atropine or a pharmaceutically acceptable salt thereof is present in the ophthalmic atropine composition in an amount of between 0.001 wt% and 0.01 wt%, wherein the low-strength buffer comprises monobasic and dibasic sodium phosphate, and wherein the ophthalmic atropine composition has a pH of between 5.5 (+/- 0.2) and 6.0 (+/- 0.2).

19. The composition of claim 1, wherein the atropine or a pharmaceutically acceptable salt thereof is present in the ophthalmic atropine composition in an amount of between 0.001 wt% and 0.01 wt%, wherein the ophthalmic atropine composition further comprises a chelator in an amount of 0.01wt% (+/- 20% abs.) of the ophthalmic atropine composition, and wherein the ophthalmic atropine composition has a pH of between 5.5 (+/- 0.2) and 6.0 (+/- 0.2)

20. The composition of claim 1, wherein the low-strength buffer comprises monobasic and dibasic sodium phosphate, wherein the composition further comprises a chelator in an amount of 0.01wt% (+/- 20% abs.) of the ophthalmic atropine composition, wherein the ophthalmic atropine composition has a pH of between 5.5 (+/- 0.2) and 6.0 (+/- 0.2), wherein the salt is present in the ophthalmic atropine composition in an amount of 0.5 wt% ( +/- 0.2 wt%), and wherein the cellulosic viscosity modifier is present in an amount of 0.5 wt% (+/- 0.1 wt%) of the ophthalmic atropine composition.